Utilizing the Lactate Dehydrogenase-to-Albumin Ratio for Survival Prediction in Patients with Bladder Cancer After Radical Cystectomy

References

• Miller KD, Nogueira L, Devasia T, et al. Cancer treatment and survivorship statistics, 2022. CA Cancer J Clin. 2022;72:409.
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, Rodríguez O, Hernández V, et al. European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: an Update from the EAU NMIBC Guidelines Panel. Eur Urol. 2021;79(4):480–488.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33.
   PubMed Web of Science ®Google Scholar
• Babjuk M, Burger M, Capoun O, et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ). Eur Urol. 2022;81(1):75–94.
   PubMed Web of Science ®Google Scholar
• Witjes JA, Bruins HM, Cathomas R, et al. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: summary of the 2020 Guidelines. Eur Urol. 2021;79(1):82–104.
   PubMed Web of Science ®Google Scholar
• Tamalunas A, Volz Y, Schlenker BA, et al. Is It Safe to Offer Radical Cystectomy to Patients above 85 Years of Age? A Long-Term Follow-Up in a Single-Center Institution. Urol Int. 2020;104(11–12):975–981.
   PubMedGoogle Scholar
• Alexopoulos G, Zhang J, Karampelas I, et al. Long-Term Time Series Forecasting and Updates on Survival Analysis of Glioblastoma Multiforme: a 1975–2018 Population-Based Study. Neuroepidemiology. 2022;56(2):75–89.
   PubMedGoogle Scholar
• Herzberg H, Lifshitz K, Golan S, et al. Association between early change in neutrophil-to-lymphocyte ratio after radical cystectomy and treatment outcomes. BJU Int. 2022;72:409.
   Google Scholar
• Rajwa P, Życzkowski M, Paradysz A, Bujak K, Bryniarski P. Evaluation of the prognostic value of LMR, PLR, NLR, and dNLR in urothelial bladder cancer patients treated with radical cystectomy. Eur Rev Med Pharmacol Sci. 2018;22(10):3027–3037.
   PubMedGoogle Scholar
• Peng D, Gong YQ, Hao H, et al. Preoperative Prognostic Nutritional Index is a Significant Predictor of Survival with Bladder Cancer after Radical Cystectomy: a retrospective study. BMC Cancer. 2017;17(1):391.
   PubMedGoogle Scholar
• Peng L, Du C, Meng C, et al. Controlling Nutritional Status Score Before Receiving Treatment as a Prognostic Indicator for Patients With Urothelial Cancer: an Exploration Evaluation Methods. Front Oncol. 2021;11:702908.
   PubMedGoogle Scholar
• Doherty JR, Cleveland JL. Targeting lactate metabolism for cancer therapeutics. J Clin Invest. 2013;123(9):3685–3692.
   PubMed Web of Science ®Google Scholar
• Zhang J, Yao YH, Li BG, Yang Q, Zhang PY, Wang HT. Prognostic value of pretreatment serum lactate dehydrogenase level in patients with solid tumors: a systematic review and meta-analysis. Sci Rep. 2015;5:9800.
   PubMed Web of Science ®Google Scholar
• Li J, Cheng Y, Liu G, Ji Z. The association of pretreatment serum albumin with outcomes in bladder cancer: a meta-analysis. Onco Targets Ther. 2018;11:3449–3459.
   PubMed Web of Science ®Google Scholar
• Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017;67(2):93–99.
   PubMed Web of Science ®Google Scholar
• Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: prostate and Bladder Tumours. Eur Urol. 2016;70(1):106–119.
   PubMed Web of Science ®Google Scholar
• Compérat EM, Burger M, Gontero P, et al. Grading of Urothelial Carcinoma and The New “World Health Organisation Classification of Tumours of the Urinary System and Male Genital Organs 2016”. Eur Urol Focus. 2019;5(3):457–466.
   PubMedGoogle Scholar
• Hanahan D. Hallmarks of Cancer: new Dimensions. Cancer Discov. 2022;12(1):31–46.
   PubMed Web of Science ®Google Scholar
• Park JH, Pyun WY, Park HW. Cancer Metabolism: phenotype, Signaling and Therapeutic Targets. Cells. 2020;9:10.
   Web of Science ®Google Scholar
• Bullock AF, Greenley SL, McKenzie GAG, Paton LW, Johnson MJ. Relationship between markers of malnutrition and clinical outcomes in older adults with cancer: systematic review, narrative synthesis and meta-analysis. Eur J Clin Nutr. 2020;74(11):1519–1535.
   PubMed Web of Science ®Google Scholar
• Mertens LS, Claps F, Mayr R, et al. Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients. Urol Oncol. 2022;40(3):110.e111–110.e119.
   Google Scholar
• Mori K, Miura N, Mostafaei H, et al. Prognostic value of preoperative hematologic biomarkers in urothelial carcinoma of the bladder treated with radical cystectomy: a systematic review and meta-analysis. Int J Clin Oncol. 2020;25(8):1459–1474.
   PubMed Web of Science ®Google Scholar
• Mayr R, Fritsche HM, Zeman F, et al. Sarcopenia predicts 90-day mortality and postoperative complications after radical cystectomy for bladder cancer. World J Urol. 2018;36(8):1201–1207.
   PubMed Web of Science ®Google Scholar
• Claps F, van de Kamp MW, Mayr R, et al. Risk factors associated with positive surgical margins’ location at radical cystectomy and their impact on bladder cancer survival. World J Urol. 2021;39(12):4363–4371.
   PubMedGoogle Scholar
• Claps F, Mir MC, Zargar H. Molecular markers of systemic therapy response in urothelial carcinoma. Asian J Urol. 2021;8(4):376–390.
   PubMedGoogle Scholar
• Mir MC, Campi R, Loriot Y, et al. Adjuvant Systemic Therapy for High-risk Muscle-invasive Bladder Cancer After Radical Cystectomy: current Options and Future Opportunities. Eur Urol Oncol. 2021;2:56.
   Google Scholar
• Cheng Q, Gu L, Zhao X, et al. A new index (A/G) associated with early complications of radical cystectomy and intestinal urinary diversion. Urol Oncol. 2021;39(5):301.e311–301.e316.
   Google Scholar
• Claps F, Rai S, Mir MC, et al. Prognostic value of preoperative albumin-to-fibrinogen ratio (AFR) in patients with bladder cancer treated with radical cystectomy. Urol Oncol. 2021;39(12):835.e839–835.e817.
   Google Scholar
• Liu J, Dai Y, Zhou F, et al. The prognostic role of preoperative serum albumin/globulin ratio in patients with bladder urothelial carcinoma undergoing radical cystectomy. Urol Oncol. 2016;34(11):484.e481–484.e488.
   Web of Science ®Google Scholar
• Tamalunas A, Buchner A, Kretschmer A, et al. Impact of Routine Laboratory Parameters in Patients Undergoing Radical Cystectomy for Urothelial Carcinoma of the Bladder: a Long-Term Follow-Up. Urol Int. 2020;104(7–8):551–558.
   PubMed Web of Science ®Google Scholar
• Gan W, Zhang MX, Wang JX, et al. Prognostic impact of lactic dehydrogenase to albumin ratio in hepatocellular carcinoma patients with Child-Pugh I who underwent curative resection: a prognostic nomogram study. Cancer Manag Res. 2018;10:5383–5394.
   PubMed Web of Science ®Google Scholar
• Gao S, Wu M, Chen Y, et al. Lactic dehydrogenase to albumin ratio in prediction of unresectable pancreatic cancer with intervention chemotherapy. Future Oncol. 2018;14(14):1377–1386.
   PubMedGoogle Scholar
• Feng JF, Wang L, Yang X, Jiang YH. Prognostic value of lactate dehydrogenase to albumin ratio (LAR) in patients with resectable esophageal squamous cell carcinoma. Cancer Manag Res. 2019;11:7243–7251.
   PubMed Web of Science ®Google Scholar
• Peng RR, Liang ZG, Chen KH, Li L, Qu S, Zhu XD. Nomogram Based on Lactate Dehydrogenase-to-Albumin Ratio (LAR) and Platelet-to-Lymphocyte Ratio (PLR) for Predicting Survival in Nasopharyngeal Carcinoma. J Inflamm Res. 2021;14:4019–4033.
   PubMed Web of Science ®Google Scholar
• Zhao R, Liang Z, Chen K, Zhu X. Nomogram Based on Inflammatory Biomarkers and Nutritional Indicators for Predicting Overall Survival in Locoregionally Advanced Nasopharyngeal Carcinoma. J Inflamm Res. 2022;15:2971–2981.
   PubMed Web of Science ®Google Scholar
• Nakazawa N, Sohda M, Yamaguchi A, et al. An Elevated Serum Lactate Dehydrogenase-to-albumin Ratio Is a Useful Poor Prognostic Predictor of Nivolumab in Patients With Gastric Cancer. Anticancer Res. 2021;41(8):3925–3931.
   PubMedGoogle Scholar
• Hu Y, Zhou Y, Cao Y, et al. Nomograms based on lactate dehydrogenase to albumin ratio for predicting survival in colorectal cancer. Int J Med Sci. 2022;19(6):1003–1012.
   PubMedGoogle Scholar
• Xie Z, Zhou H, Wang L, Wu Y. The Significance of the preoperative lactate dehydrogenase/albumin Ratio in the Prognosis of Colon Cancer: a retrospective study. PeerJ. 2022;10:e13091.
   PubMedGoogle Scholar